TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Brief Summary: The study was designed to evaluate the efficacy and safety of fingolimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy compared with placebo.


Options:
A: Arm Label: Interferon beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Placebo to ozanimod | Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Placebo to interferon beta-1a | Arm Label: Ozanimod 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Placebo to interferon beta-1a | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a | Intervention Type: DRUG; Name: Placebo to ozanimod; Assigned to Arm(s): Interferon beta-1a | Intervention Type: DRUG; Name: Placebo to interferon beta-1a; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg
B: Arm Label: Fingolimod (FTY720); Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod (FTY720) | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: peginterferon beta-1a, Drug: Rebif | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: peginterferon beta-1a, Drug: Rebif | Intervention Type: DRUG; Name: peginterferon beta-1a; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Rebif; Assigned to Arm(s): Group 1, Group 2
D: Arm Label: GA 20 mg/mL every day; Type: ACTIVE_COMPARATOR; Interventions: Drug: GA 20 mg/mL | Arm Label: GA 40 mg/mL 3 times a week; Type: EXPERIMENTAL; Interventions: Drug: GA 40 mg/mL | Intervention Type: DRUG; Name: GA 20 mg/mL; Assigned to Arm(s): GA 20 mg/mL every day | Intervention Type: DRUG; Name: GA 40 mg/mL; Assigned to Arm(s): GA 40 mg/mL 3 times a week

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Perineal trauma is common during vaginal birth. The discomfort this causes can interfere with a woman's recovery and early motherhood.Mothers are offered a standard treatment after childbirth, water soaked frozen peri pads (ice packs), to alleviate the discomfort. However, a Cochrane review questions the efficacy of ice packs treatment. An alternative treatment that may be more comfortable and effective for women is warm water soaked black tea bags. Medicinal use of black tea bags has been based on their astringent (shrinking or constricting) properties and have been used for various medical applications.

The investigators will conduct a pilot randomized controlled trial (RCT) of 40 pregnant mothers randomized to either intervention group (tea bags; n=20) or control group (ice packs; n=20). The goal of this pilot is to test the feasibility of a larger RCT by assessing recruitment, testing the protocol, and evaluating a proposed primary outcome objective of analgesic use during hospitalization as an indicator of pain. The investigators expect this pilot study to demonstrate feasibility for a large scale RCT to formally evaluate the efficacy of black tea bags to reduce perineal pain in this patient population.


Options:
A: Arm Label: Black tea bag; Type: EXPERIMENTAL; Interventions: Other: Warm water soaked Black Tea Bags | Arm Label: ice packs; Type: ACTIVE_COMPARATOR; Interventions: Other: Frozen perineal pad | Intervention Type: OTHER; Name: Frozen perineal pad; Assigned to Arm(s): ice packs | Intervention Type: OTHER; Name: Warm water soaked Black Tea Bags; Assigned to Arm(s): Black tea bag
B: Arm Label: Binder Arm; Type: EXPERIMENTAL; Interventions: Device: Abdominal binder | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Abdominal binder; Assigned to Arm(s): Binder Arm
C: Arm Label: Post-partum primi and multiparous women; Type: EXPERIMENTAL; Interventions: Device: Leboride | Arm Label: Post-partum women that have already begun breast feeding; Type: EXPERIMENTAL; Interventions: Device: Leboride | Intervention Type: DEVICE; Name: Leboride; Assigned to Arm(s): Post-partum primi and multiparous women, Post-partum women that have already begun breast feeding
D: Arm Label: Magnesium sulfate; Type: ACTIVE_COMPARATOR; Interventions: Other: Cold pads soaked in Magnesium sulfate solution | Arm Label: Water; Type: SHAM_COMPARATOR; Interventions: Other: Cold pads soaked in water | Intervention Type: OTHER; Name: Cold pads soaked in Magnesium sulfate solution; Assigned to Arm(s): Magnesium sulfate | Intervention Type: OTHER; Name: Cold pads soaked in water; Assigned to Arm(s): Water

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double Blinded Controlled Trial of an Oral Nutritional Supplement Containing AN 777 in Older Hospitalized Patients
Brief Summary: Evaluate effects of an oral nutritional supplement on healthcare outcomes in older hospitalized adults. Also referred to as the NOURISH Study - Nutrition effect On Unplanned Readmissions and Survival in Hospitalized patients.


Options:
A: Arm Label: Ready to drink flavored beverage; Type: PLACEBO_COMPARATOR; Interventions: Other: Ready to Drink Flavored Beverage | Arm Label: Ready to drink flavored beverage w/ AN 777; Type: EXPERIMENTAL; Interventions: Other: Ready to drink flavored beverage w/ AN 777 | Intervention Type: OTHER; Name: Ready to Drink Flavored Beverage; Assigned to Arm(s): Ready to drink flavored beverage | Intervention Type: OTHER; Name: Ready to drink flavored beverage w/ AN 777; Assigned to Arm(s): Ready to drink flavored beverage w/ AN 777
B: Arm Label: Protein enriched yoghurt drink and bread; Type: EXPERIMENTAL; Interventions: Other: Protein enriched yoghurt drink and bread | Arm Label: Regular yoghurt drink and bread; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Protein enriched yoghurt drink and bread; Assigned to Arm(s): Protein enriched yoghurt drink and bread
C: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as usual | Arm Label: Received nutrition supplement as needed; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Nutritional supplement, Other: Treatment as usual | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutritional supplement; Assigned to Arm(s): Received nutrition supplement as needed | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): Control, Received nutrition supplement as needed
D: Intervention Type: BEHAVIORAL; Name: Nutritional programme; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Proof of Concept Study in Male and Female Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury
Brief Summary: The purpose of this study is to assess the effect of orally inhaled AP301 on alveolar liquid clearance in ALI (acute lung injury) patients with the purpose to assess the treatment associated changes of extravascular lung water (EVLW) within 7 days of treatment.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Hydrocortisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone
B: Intervention Type: DRUG; Name: HL 10; Assigned to Arm(s): N/A
C: Arm Label: AP301; Type: EXPERIMENTAL; Interventions: Drug: AP301 | Arm Label: saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline solution | Intervention Type: DRUG; Name: AP301; Assigned to Arm(s): AP301 | Intervention Type: DRUG; Name: Saline solution; Assigned to Arm(s): saline solution
D: Arm Label: Albuterol Sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albuterol Sulfate, Procedure: Mini-Bronchoalveolar Lavage (BAL) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Mini-Bronchoalveolar Lavage (BAL), Drug: Placebo | Intervention Type: DRUG; Name: Albuterol Sulfate; Assigned to Arm(s): Albuterol Sulfate | Intervention Type: PROCEDURE; Name: Mini-Bronchoalveolar Lavage (BAL); Assigned to Arm(s): Albuterol Sulfate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Brief Summary: This study is a two-part trial consisting of Part A (presented in this record) and Part B (see NCT02047734).

The primary objective in Part A of this study was to demonstrate the superior efficacy of ozanimod compared to placebo by showing a reduction in the cumulative number of total gadolinium-enhancing (GdE) lesions from Week 12 to Week 24 in patients with relapsing multiple sclerosis (RMS).


Options:
A: Arm Label: Threshold estimates; Type: EXPERIMENTAL; Interventions: Other: descriptive case-scenarios | Arm Label: Alternative threshold estimates; Type: ACTIVE_COMPARATOR; Interventions: Other: descriptive case-scenarios | Intervention Type: OTHER; Name: descriptive case-scenarios; Assigned to Arm(s): Alternative threshold estimates, Threshold estimates
B: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
D: Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod | Arm Label: Ozanimod 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ozanimod, Drug: Placebo | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Point-of-Choice Prompts to Reduce Prolonged Sitting Time at Work: A Randomised Trial
Brief Summary: The purpose of this study is to determine whether an on-screen prompt put on the work computer every 30 minutes is effective in getting office workers to reduce prolonged periods of sitting at work.


Options:
A: Arm Label: Lifestyle change; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction of sedentary time by breaking it with low intensity physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reduction of sedentary time by breaking it with low intensity physical activity; Assigned to Arm(s): Lifestyle change
B: Arm Label: Novel workplace - first half; Type: EXPERIMENTAL; Interventions: Other: Workplace consisting of two height-adjustable desks | Arm Label: Novel workplace - second half; Type: EXPERIMENTAL; Interventions: Other: Workplace consisting of two height-adjustable desks | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Workplace consisting of two height-adjustable desks; Assigned to Arm(s): Novel workplace - first half, Novel workplace - second half
C: Arm Label: tailored group; Type: EXPERIMENTAL; Interventions: Behavioral: Start to stand | Arm Label: generic group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: generic advice | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Start to stand; Assigned to Arm(s): tailored group | Intervention Type: BEHAVIORAL; Name: generic advice; Assigned to Arm(s): generic group
D: Arm Label: education only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education talk and leaflet | Arm Label: prompt + education; Type: EXPERIMENTAL; Interventions: Device: MyRestBreak 1.0, Behavioral: education talk and leaflet | Intervention Type: DEVICE; Name: MyRestBreak 1.0; Assigned to Arm(s): prompt + education | Intervention Type: BEHAVIORAL; Name: education talk and leaflet; Assigned to Arm(s): education only, prompt + education

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Point-of-Choice Prompts to Reduce Prolonged Sitting Time at Work: A Randomised Trial
Brief Summary: The purpose of this study is to determine whether an on-screen prompt put on the work computer every 30 minutes is effective in getting office workers to reduce prolonged periods of sitting at work.


Options:
A: Arm Label: High intensity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Low intensity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): High intensity intervention group, Low intensity intervention group
B: Arm Label: multi-component intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Sit-stand workstation provision | Arm Label: Sit-stand workstation only; Type: EXPERIMENTAL; Interventions: Behavioral: Sit-stand workstation provision | Arm Label: Usual practice (seated workstation); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sit-stand workstation provision; Assigned to Arm(s): Sit-stand workstation only, multi-component intervention
C: Arm Label: education only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education talk and leaflet | Arm Label: prompt + education; Type: EXPERIMENTAL; Interventions: Device: MyRestBreak 1.0, Behavioral: education talk and leaflet | Intervention Type: DEVICE; Name: MyRestBreak 1.0; Assigned to Arm(s): prompt + education | Intervention Type: BEHAVIORAL; Name: education talk and leaflet; Assigned to Arm(s): education only, prompt + education
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ALIVE | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ALIVE; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Point-of-Choice Prompts to Reduce Prolonged Sitting Time at Work: A Randomised Trial
Brief Summary: The purpose of this study is to determine whether an on-screen prompt put on the work computer every 30 minutes is effective in getting office workers to reduce prolonged periods of sitting at work.


Options:
A: Arm Label: Sitting time Change Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Sitting time Change Intervention | Arm Label: Active Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sitting time Change Intervention; Assigned to Arm(s): Sitting time Change Intervention
B: Arm Label: Lifestyle change; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction of sedentary time by breaking it with low intensity physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reduction of sedentary time by breaking it with low intensity physical activity; Assigned to Arm(s): Lifestyle change
C: Arm Label: education only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education talk and leaflet | Arm Label: prompt + education; Type: EXPERIMENTAL; Interventions: Device: MyRestBreak 1.0, Behavioral: education talk and leaflet | Intervention Type: DEVICE; Name: MyRestBreak 1.0; Assigned to Arm(s): prompt + education | Intervention Type: BEHAVIORAL; Name: education talk and leaflet; Assigned to Arm(s): education only, prompt + education
D: Arm Label: multi-component intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Sit-stand workstation provision | Arm Label: Sit-stand workstation only; Type: EXPERIMENTAL; Interventions: Behavioral: Sit-stand workstation provision | Arm Label: Usual practice (seated workstation); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sit-stand workstation provision; Assigned to Arm(s): Sit-stand workstation only, multi-component intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase II Study of BEZ235 or Everolimus in Advanced Pancreatic Neuroendocrine Tumors
Brief Summary: This was a multicenter, open label, randomized phase II study to evaluate the efficacy and safety of BEZ235 as compared to everolimus in patients with advanced, low to intermediate grade pancreatic neuroendocrine tumor (pNET).


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: sunitinib malate | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: sunitinib malate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: BEZ235; Type: EXPERIMENTAL; Interventions: Drug: BEZ235 | Arm Label: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: BEZ235; Assigned to Arm(s): BEZ235 | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus
C: Arm Label: lanreotide; Type: EXPERIMENTAL; Interventions: Drug: lanreotide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lanreotide; Assigned to Arm(s): lanreotide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Surufatinib; Type: EXPERIMENTAL; Interventions: Drug: Surufatinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Surufatinib; Assigned to Arm(s): Surufatinib | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy: a Randomized Double-blind Trial (ERIKA Study)
Brief Summary: Study Objective: To assess the value of Rivaroxaban for the prevention of venous thromboembolism (VTE) after knee arthroscopy (KA) taking the placebo as standard of reference.

Study Population: Patients undergoing therapeutic KA at the study Centers, irrespective of the type and duration of the procedure, will be eligible for the study.

Study Design: Multicenter, randomized, double blind superiority, phase II trial comparing two arms:

* (R-7d) Rivaroxaban (10 mg od os) for 7 days
* (PL-7d) Placebo for 7 days.

Follow-up: 3-month period after the randomization

Standard of Reference:Placebo will be the standard of reference in accordance to international guidelines

Study length May 2012-December 2012

Total patients number: 500 patients

Primary Efficacy End-Point: Occurrence in the 3-month period after the randomization of at least one of the following events, objectively proven (by means of CCDU; multi-slice chest TC-angio; autopsy, if necessary, or clinical ground):

* All-cause mortality
* Symptomatic VTE
* Asymptomatic proximal DVT

Secondary Efficacy End-point:

• Combined incidence of all DVT plus symptomatic PE

Primary Safety End-point: Incidence of major bleedings.

Secondary Safety End-point: Overall incidence of bleeding


Options:
A: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH
B: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH
C: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: DRY group; Type: ACTIVE_COMPARATOR; Interventions: Other: Dry sheet Therapeutic body wraps | Arm Label: WET Group; Type: EXPERIMENTAL; Interventions: Other: WET sheet Therapeutic body wraps | Intervention Type: OTHER; Name: Dry sheet Therapeutic body wraps; Assigned to Arm(s): DRY group | Intervention Type: OTHER; Name: WET sheet Therapeutic body wraps; Assigned to Arm(s): WET Group

Answer: C